Advertisement

Clinical & Experimental Metastasis

, Volume 22, Issue 7, pp 559–564 | Cite as

Low-dose Methotrexate Inhibits Lung Metastasis and Lengthens Survival in Rat Osteosarcoma

  • Ryota TomodaEmail author
  • Masashi Seto
  • Yasunari Hioki
  • Jun Sonoda
  • Akihiko Matsumine
  • Katsuyuki Kusuzaki
  • Atsumasa Uchida
Article

Abstract

Lung metastasis is the most crucial event affecting the treatment of osteosarcoma and is dependent on tumor angiogenesis. To improve the prognosis for patients with osteosarcoma, prevention of lung metastasis is essential. Low-dose methotrexate is a useful drug for treating a variety of diseases. Low-dose methotrexate reportedly plays a role in antiangiogenesis for the synovial blood vessels in rheumatoid arthritis. However, whether low-dose methotrexate is correlated with tumor angiogenesis and metastasis is unclear. We investigated the inhibitory effect of methotrexate on lung metastasis in a rat osteosarcoma cell line with high metastatic potential, S-SLM. Two weeks after inoculation of S-SLM cells into male Fischer 344 rats, low-dose methotrexate (1.2 mg/kg once or twice a week) or saline was intraperitonealy injected for 4 weeks and the antimetastatic effect was evaluated. Low-dose methotrexate significantly reduced the number of lung metastatic nodules and the wet weight of the lungs. Immunohistochemical staining showed a decrease in microvessel density in the metastatic nodules. We also evaluated the effect of methotrexate on the proliferation of endothelial cells and S-SLM osteosarcoma cells in vitro. Methotrexate significantly inhibited the proliferation of endothelial cells at a lower concentration than that of S-SLM osteosarcoma cells. These data suggest that low-dose methotrexate inhibited lung metastasis of osteosarcoma through its antiangiogenic activity. Our results indicate that low-dose methotrexate is a promising drug for tumor dormancy therapy in patients with osteosarcoma and lung metastasis.

Keywords

angiogenesis low-dose methotrexate metastasis osteosarcoma 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Rosen, G, Suwansirikul, S, Kwon, C,  et al. 1974High-dose methotrexate with citrovorum factor rescue and adriamycin in childhood osteogenic sarcomaCancer33115163PubMedGoogle Scholar
  2. 2.
    Jaffe, N, Frei, E,3rd, Traggis, D,  et al. 1974Adjuvant methotrexate and citrovorum-factor treatment of osteogenic sarcomaN Engl J Med2919947PubMedGoogle Scholar
  3. 3.
    Rosen, G, Marcove, RC, Caparros, B,  et al. 1979Primary osteogenic sarcoma: the rationale for preoperative chemotherapy and delayed surgeryCancer43216377PubMedGoogle Scholar
  4. 4.
    Winkler, K, Beron, G, Delling, G,  et al. 1988Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor responseJ Clin Oncol632937PubMedGoogle Scholar
  5. 5.
    Saeter, G, Alvegard, TA, Elomaa, I,  et al. 1991Treatment of osteosarcoma of the extremities with the T-10 protocol, with emphasis on the effects of preoperative chemotherapy with single-agent high-dose methotrexate: a Scandinavian Sarcoma Group studyJ Clin Oncol9176675PubMedGoogle Scholar
  6. 6.
    Meyers, PA, Heller, G, Healey, J,  et al. 1992Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experienceJ Clin Oncol10515PubMedGoogle Scholar
  7. 7.
    Uchida, A, Myoui, A, Araki, N,  et al. 1997Neoadjuvant chemotherapy for pediatric osteosarcoma patientsCancer794115CrossRefPubMedGoogle Scholar
  8. 8.
    Bacci, G, Picci, P, Ferrari, S,  et al. 1993Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicinCancer72322738PubMedGoogle Scholar
  9. 9.
    Meyers, PA, Heller, G, Healey, JH,  et al. 1993Osteogenic sarcoma with clinically detectable metastasis at initial presentationJ Clin Oncol1144953PubMedGoogle Scholar
  10. 10.
    Folkman, J 1971Tumor angiogenesis: therapeutic implicationsN Engl J Med28511826PubMedGoogle Scholar
  11. 11.
    Weidner, N, Semple, JP, Welch, WR,  et al. 1991Tumor angiogenesis and metastasis – correlation in invasive breast carcinomaN Engl J Med32418PubMedGoogle Scholar
  12. 12.
    Hirata, S, Matsubara, T, Saura, R,  et al. 1989Inhibition of in vitro vascular endothelial cell proliferation and in vivo neovascularization by low-dose methotrexateArthritis Rheum32106573PubMedGoogle Scholar
  13. 13.
    Nagashima, M, Yoshino, S, Aono, ,  et al. 1999Inhibitory effects of anti-rheumatic drugs on vascular endothelial growth factor in cultured rheumatoid synovial cellsClin Exp Immunol1163605CrossRefPubMedGoogle Scholar
  14. 14.
    Honoki, K, Tsutsumi, M, Miyauchi, Y,  et al. 1993Increased expression of nucleoside diphosphate kinase/nm23 and c-Ha-ras mRNA is associated with spontaneous lung metastasis in rat-transplantable osteosarcomasCancer Res53503842PubMedGoogle Scholar
  15. 15.
    Morishita, T, Mii, Y, Miyauchi, Y,  et al. 1995Efficacy of the angiogenesis inhibitor O-(chloroacetyl-carbamoyl)fumagillol (AGM-1470) on osteosarcoma growth and lung metastasis in ratsJpn J Clin Oncol252531PubMedGoogle Scholar
  16. 16.
    Kido, A, Tsutsumi, M, Iki, K,  et al. 1999Inhibition of spontaneous rat osteosarcoma lung metastasis by 3S-[4-(N-hydroxyamino)-2R-isobutylsuccinyl]amino-1-methoxy-3,4-dihydroc arbostyril, a novel matrix metalloproteinase inhibitorJpn J Cancer Res9033341PubMedGoogle Scholar
  17. 17.
    Kido, A, Tsutsumi, M, Iki, K,  et al. 1999Overexpression of matrix metalloproteinase (MMP)-9 correlates with metastatic potency of spontaneous and 4-hydroxyaminoquinoline 1-oxide (4-HAQO)-induced transplantable osteosarcomas in ratsCancer Lett13720916CrossRefPubMedGoogle Scholar
  18. 18.
    Weidner, N, Folkman, J, Pozza, F,  et al. 1992Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinomaJ Natl Cancer Inst84187587PubMedGoogle Scholar
  19. 19.
    Macchiarini, P, Fontanini, G, Hardin, MJ,  et al. 1992Relation of neovascularisation to metastasis of non-small-cell lung cancerLancet3401456CrossRefPubMedGoogle Scholar
  20. 20.
    Weidner, N, Carroll, PR, Flax, J,  et al. 1993Tumor angiogenesis correlates with metastasis in invasive prostate carcinomaAm J Pathol1434019PubMedGoogle Scholar
  21. 21.
    Kaya, M, Wada, T, Akatsuka, T,  et al. 2000Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosisClin Cancer Res65727PubMedGoogle Scholar
  22. 22.
    Cronstein, BN, Naime, D, Ostad, E 1993The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammationJ Clin Invest92267582PubMedGoogle Scholar
  23. 23.
    Mori, S, Ueda, T, Kuratsu, S,  et al. 1995Suppression of pulmonary metastasis by angiogenesis inhibitor TNP-470 in murine osteosarcomaInt J Cancer6114852PubMedGoogle Scholar
  24. 24.
    Ahmed, MH, Konno, H, Nahar, L,  et al. 1996The angiogenesis inhibitor TNP-470 (AGM-1470) improves long-term survival of rats with liver metastasisJ Surg Res643541CrossRefPubMedGoogle Scholar
  25. 25.
    Naglich, JG, Jure-Kunkel, M, Gupta, E,  et al. 2001Inhibition of angiogenesis and metastasis in two murine models by the matrix metalloproteinase inhibitor, BMS-275291Cancer Res6184805PubMedGoogle Scholar
  26. 26.
    Katori, H, Baba, Y, Imagawa, Y,  et al. 2002Reduction of in vivo tumor growth by MMI-166, a selective matrix metalloproteinase inhibitor, through inhibition of tumor angiogenesis in squamous cell carcinoma cell lines of head and neckCancer Lett1781519CrossRefPubMedGoogle Scholar

Copyright information

© Springer 2006

Authors and Affiliations

  • Ryota Tomoda
    • 1
    • 2
    Email author
  • Masashi Seto
    • 1
  • Yasunari Hioki
    • 1
  • Jun Sonoda
    • 1
  • Akihiko Matsumine
    • 1
  • Katsuyuki Kusuzaki
    • 1
  • Atsumasa Uchida
    • 1
  1. 1.Department of Orthopedic SurgeryMie University School of MedicineTsuJapan
  2. 2.Department of Orthopedic SurgeryMie University School of MedicineTsuJapan

Personalised recommendations